EDAP's Ablatherm-HIFU Demonstrates Long-Term Efficacy and Safety Over Fourteen-Year Period
Longest Retrospective Study of HIFU Patients to Date Published Confirms Benefits of Treatment
LYON, France, Feb. 8, 2013 -- (Healthcare Sales & Marketing Network) -- EDAP TMS SA (EDAP), the global leader in therapeutic ultrasound, announced today new da... Devices, OncologyEDAP TMS, Ablatherm-HIFU, ultrasound guided HIFU, prostate cancer
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news
More News: Cancer | Cancer & Oncology | High Intensity Focused Ultrasound Therapy | Marketing | Pharmaceuticals | Prostate Cancer | Study | Ultrasound